Related references
Note: Only part of the references are listed.Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Sameer Ansar et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
R. Gomis et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications
Sanjay Kalra et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2011)
Glycemic Control and Complications in Type 2 Diabetes Mellitus
Mark Stolar
AMERICAN JOURNAL OF MEDICINE (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Jay S. Skyler et al.
DIABETES CARE (2009)
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies
Kiwon Ban et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Comparison of the Numerical and Clinical Accuracy of Four Continuous Glucose Monitors: Response to Brauker and Matsubara
B. Kovatchev et al.
DIABETES CARE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The pathobiology of diabetic complications - A unifying mechanism
M Brownlee
DIABETES (2005)
Share Paper
